PFE and BMY Related Headlines

Go Back

Aug 24, 2015 08:20AM Bristol-Myers Squibb (BMY), Pfizer (PFE) to Present Eliquis Data at ESC Congress
Jul 31, 2015 09:57AM Bristol-Myers Squibb (BMY) Active Amid Unconfirmed Chatter
Jun 22, 2015 08:47AM Portola Pharma (PTLA), Bristol-Myers (BMY), Pfizer (PFE) Announce Second Part of Phase 3 ANNEXA-A Met All Primary, Secondary Endpoints
Apr 13, 2015 10:26AM Bristol-Myers Squibb (BMY) Active on M&A Chatter
Dec 8, 2014 01:36PM Bristol-Myers Squibb (BMY), Pfizer (PFE) Report Anticoagulant Effect of Eliquis Presented at AHS
Dec 5, 2014 10:00AM Bristol-Myers Squibb (BMY) Active on Chatter
Dec 4, 2014 10:22AM Jefferies Names Top 2015 Pharmaceutical Picks (PFE) (NVS) (more...)
Nov 17, 2014 08:02AM Significant Results Announced for First Part of Phase 3 ANNEXA-A (PTLA) (BMY) (PFE)
Oct 1, 2014 08:17AM Portola Pharma (PTLA) Reports Andexanet Alfa Phase 3 Met Primary Endpoint

PFE and BMY Related Press Releases

Go Back

Aug 24, 2015 08:15AM Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis (apixaban) at the ESC Congress 2015
Jun 22, 2015 08:45AM Portola, Bristol-Myers Squibb and Pfizer Announce Full Results of Second Part of Phase 3 ANNEXA-A(TM) Study Demonstrating That Investigational Andexanet Alfa Sustained Reversal of Anticoagulant Effect
Jun 22, 2015 08:45AM Portola, Bristol-Myers Squibb and Pfizer Announce Full Results of Second Part of Phase 3 ANNEXA-A(TM) Study Demonstrating That Investigational Andexanet Alfa Sustained Reversal of Anticoagulant Effect

PFE and BMY Related SEC Filings

Go Back